{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:32:59Z","timestamp":1793727179305,"version":"4.6.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004479","name":"Jiangxi Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.clim.2026.110785","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:39:46Z","timestamp":1792276786000},"page":"110785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Genetic and clinical evidence supports HLA-DR+ CD8+ T cells as a favorable immune biomarker in acute myeloid leukemia"],"prefix":"10.1016","volume":"288","author":[{"given":"Gang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linhui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.clim.2026.110785_bb0005","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","article-title":"Genomics of acute myeloid leukemia diagnosis and pathways","volume":"35","author":"Bullinger","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"10159","key":"10.1016\/j.clim.2026.110785_bb0010","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","article-title":"Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories","volume":"392","author":"Foreman","year":"2018","journal-title":"Lancet"},{"issue":"10147","key":"10.1016\/j.clim.2026.110785_bb0015","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clim.2026.110785_bb0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2015-07-604496","article-title":"Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance","volume":"127","author":"Grimwade","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clim.2026.110785_bb0025","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","article-title":"An update of current treatments for adult acute myeloid leukemia","volume":"127","author":"Dombret","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clim.2026.110785_bb0030","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clim.2026.110785_bb0035","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01424-6","article-title":"Recent advances in targeted therapies in acute myeloid leukemia","volume":"16","author":"Bhansali","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.clim.2026.110785_bb0040","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","article-title":"Systemic immunity in cancer","volume":"21","author":"Hiam-Galvez","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"21","key":"10.1016\/j.clim.2026.110785_bb0045","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120974","article-title":"Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy","volume":"3","author":"Knaus","year":"2018","journal-title":"JCI Insight"},{"issue":"21","key":"10.1016\/j.clim.2026.110785_bb0050","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159579","article-title":"Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia","volume":"132","author":"Rutella","year":"2022","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.clim.2026.110785_bb0055","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s12185-016-2153-5","article-title":"Bone marrow T-cell percentage: a novel prognostic indicator in acute myeloid leukemia","volume":"105","author":"Ismail","year":"2017","journal-title":"Int. J. Hematol."},{"issue":"25","key":"10.1016\/j.clim.2026.110785_bb0060","doi-asserted-by":"crossref","first-page":"14331","DOI":"10.1073\/pnas.1916206117","article-title":"Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia","volume":"117","author":"Lamble","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.clim.2026.110785_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11010029","article-title":"NK cell-based immunotherapy in cancer metastasis","volume":"11","author":"Lorenzo-Herrero","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clim.2026.110785_bb0070","doi-asserted-by":"crossref","first-page":"6153","DOI":"10.2147\/JIR.S388993","article-title":"Peripheral blood lymphocyte subsets as a risk predictor of patients with endometrioid endometrial cancer","volume":"15","author":"Su","year":"2022","journal-title":"J. Inflamm. Res."},{"issue":"R1","key":"10.1016\/j.clim.2026.110785_bb0075","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1093\/hmg\/ddu328","article-title":"Mendelian randomization: genetic anchors for causal inference in epidemiological studies","volume":"23","author":"Davey Smith","year":"2014","journal-title":"Hum. Mol. Genet."},{"issue":"19","key":"10.1016\/j.clim.2026.110785_bb0080","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1001\/jama.2017.17219","article-title":"Mendelian randomization","volume":"318","author":"Emdin","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.clim.2026.110785_bb0085","article-title":"Causal relationship between immune cells and acute myeloid leukemia: a two-sample Mendelian randomization study","volume":"15","author":"Yu","year":"2024","journal-title":"Discov. Oncol."},{"issue":"1","key":"10.1016\/j.clim.2026.110785_bb0090","article-title":"Mendelian randomization analysis reveals the causal relationship between immune cells and leukemia","volume":"16","author":"Lin","year":"2025","journal-title":"Discov. Oncol."},{"issue":"20","key":"10.1016\/j.clim.2026.110785_bb0095","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clim.2026.110785_bb0100","first-page":"705","article-title":"Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL)","volume":"44","author":"Leukemia Lymphoma Group, C. S. o. H., Chinese Medical Association","year":"2023","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.clim.2026.110785_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1659811","article-title":"Identification and validation of plasma protein biomarkers as therapeutic targets in acute myeloid leukemia: an integrative multi-omics study","volume":"16","author":"Hu","year":"2025","journal-title":"Front. Immunol."},{"issue":"546","key":"10.1016\/j.clim.2026.110785_bb0110","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz0463","article-title":"Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia","volume":"12","author":"Vadakekolathu","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.clim.2026.110785_bb0115","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/cdd.2014.89","article-title":"Regulation of hematopoietic and leukemic stem cells by the immune system","volume":"22","author":"Riether","year":"2015","journal-title":"Cell Death Differ."},{"issue":"6","key":"10.1016\/j.clim.2026.110785_bb0120","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/ije\/dyx207","article-title":"Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities","volume":"46","author":"Walker","year":"2017","journal-title":"Int. J. Epidemiol."},{"issue":"1","key":"10.1016\/j.clim.2026.110785_bb0125","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2219554","article-title":"Aberrant expression of T cell activation markers and upregulation of Tregs in bone marrow and peripheral blood in acute myeloid leukemia patients","volume":"28","author":"Fang","year":"2023","journal-title":"Hematology"},{"issue":"11","key":"10.1016\/j.clim.2026.110785_bb0130","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1182\/blood.2023021680","article-title":"CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia","volume":"144","author":"Mazziotta","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clim.2026.110785_bb0135","article-title":"The profile and prognostic significance of bone marrow T-cell differentiation subsets in adult AML at diagnosis","volume":"15","author":"Sun","year":"2024","journal-title":"Front. Immunol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661626001233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661626001233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:00:17Z","timestamp":1793725217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661626001233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":27,"alternative-id":["S1521661626001233"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2026.110785","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic and clinical evidence supports HLA-DR+ CD8+ T cells as a favorable immune biomarker in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2026.110785","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110785"}}